HCW Biologics Inc (HCWB) - Total Assets
Based on the latest financial reports, HCW Biologics Inc (HCWB) holds total assets worth $24.52 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HCWB equity financing ratio to measure how much of total assets are equity-financed.
HCW Biologics Inc - Total Assets Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's total assets have evolved over time, based on quarterly financial data. Explore HCWB long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
HCW Biologics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
HCW Biologics Inc's total assets of $24.52 Million consist of 9.3% current assets and 90.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.0% |
| Accounts Receivable | $32.17K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how HCW Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HCW Biologics Inc (HCWB) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HCW Biologics Inc's current assets represent 9.3% of total assets in 2025, a decrease from 79.8% in 2019.
- Cash Position: Cash and equivalents constituted 8.0% of total assets in 2025, down from 73.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
HCW Biologics Inc Competitors by Total Assets
Key competitors of HCW Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
HCW Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.19 | 7.28 |
| Quick Ratio | 0.11 | 0.19 | 6.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-18.78 Million | $-23.93 Million | $8.45 Million |
HCW Biologics Inc - Advanced Valuation Insights
This section examines the relationship between HCW Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.80 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -18.9% |
| Total Assets | $24.52 Million |
| Market Capitalization | $2.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values HCW Biologics Inc's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: HCW Biologics Inc's assets decreased by 18.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for HCW Biologics Inc (2019–2025)
The table below shows the annual total assets of HCW Biologics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $24.52 Million | -18.91% |
| 2024-12-31 | $30.24 Million | +6.04% |
| 2023-12-31 | $28.51 Million | -39.09% |
| 2022-12-31 | $46.81 Million | -12.53% |
| 2021-12-31 | $53.51 Million | +247.54% |
| 2020-12-31 | $15.40 Million | +52.97% |
| 2019-12-31 | $10.07 Million | -- |
About HCW Biologics Inc
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and … Read more